Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965283 | 1.00 | ADRB2 (0.49) | ADRB2MAPTL3MBTL1S1PR1BACE1 | |
| SCHEMBL965287 | 1.00 | ADRB2 (0.49) | ADRB2MAPTL3MBTL1S1PR1BACE1 | |
| SCHEMBL967765 | 0.90 | ADRB2 (0.45) | ADRB2BACE1TGM2 | |
| SCHEMBL967763 | 0.90 | ADRB2 (0.45) | ADRB2BACE1TGM2 | |
| SCHEMBL967764 | 0.90 | ADRB2 (0.45) | ADRB2BACE1TGM2 | |
| SCHEMBL13090610 | 0.89 | TGM2 (0.42) | ADRB2BACE1TGM2 | |
| SCHEMBL965049 | 0.83 | ADRB2 (0.56) | ADRB2TGM2KDM4E | |
| SCHEMBL965047 | 0.83 | ADRB2 (0.56) | ADRB2TGM2KDM4E | |
| SCHEMBL965046 | 0.83 | ADRB2 (0.56) | ADRB2TGM2KDM4E | |
| SCHEMBL3070143 | 0.82 | APP (0.40) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | ADRB2 40/4885MAPT 3289/4885L3MBTL1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.